Real-time enrollment status for this based on the study title "car-t followed by bispecific antibodies" and the context of car-t therapy, this appears to be treating: blood cancer clinical trial
Current Status
Recruiting
Checked: April 17, 2026 at 3:43 AM UTC
| NCT Number | NCT04889716 |
| Recruiting Status | Recruiting |
| Condition | Based on the study title "CAR-T Followed by Bispecific Antibodies" and the context of CAR-T therapy, this appears to be treating: Blood Cancer |
| Phase | Clinical Trial |
| Target Enrollment | 42 participants |
| Active Locations | 2 sites in the US |
| Sponsor | Abramson Cancer Center at Penn Medicine |
| Last Updated on CT.gov | March 18, 2026 (Mar 18, 2026) |
As of April 17, 2026: Clinical trial NCT04889716 is currently recruiting participants. This clinical trial study for based on the study title "car-t followed by bispecific antibodies" and the context of car-t therapy, this appears to be treating: blood cancer is actively seeking new participants at 2 locations across the United States. The study is sponsored by Abramson Cancer Center at Penn Medicine. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT04889716 is actively recruiting participants as of April 17, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 2 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT04889716 was last updated Mar 18, 2026 (March 18, 2026). HelloStudys verifies this status automatically.